Deutsche Bank Suspends Coverage on Valeant Pharma (VRX)

UPDATE: Canaccord Genuity Downgrades Valeant Pharmaceuticals (VRX) to Hold

(Updated - March 2, 2016 1:08 PM EST)

Canaccord Genuity downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Hold and lowered its price target to $75 (from $125). Valeant recently confirmed that it has several ongoing investigations, including investigations by the US Attorneys Offices for Massachusetts and the Southern District of New York, the SEC, and Congress.

Analyst Neil Maruoka commented... More

Valeant Pharma (VRX) Pares Earlier Decline

Valeant Pharma (NYSE: VRX) pared earlier declines to trade lower by only 1.3%.

Valeant (VRX) PT Cut to $106 at Jefferies

Jefferies analyst David Steinberg lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $106.00 (from $172.00) while maintaining a Buy rating.

Steinberg commented, "With the return of CEO Mike Pearson, a critical issue has been addressed. However, a host of equally critical questions have... More

SEC Investigation Extends Valeant Pharma's (VRX) Road to Confidence - BMO

BMO Capital analyst, Alex Arfaei, takes a stab at valuing Valeant (NYSE: VRX) while acknowledging the limited visibility into the financial impact of the investigation. No change to Market Perform rating.

The SEC investigation and the form 10-K filing delay increase concerns about the integrity of Valeants financial reporting. It is very difficult to predict the potential range of outcomes of this... More

Valeant Pharma (VRX) Provides Statement on SEC Investigation

Valeant Pharma (NYSE: VRX) said:

"In response to media inquiries, Valeant confirmed that it has several ongoing investigations, including investigations by the US Attorneys Offices for Massachusetts and the Southern District of New York, the SEC, and Congress. With respect to the SEC... More

Valeant Pharma (VRX) Affirms Receipt of SEC Subpoena

Valeant Pharma (NYSE: VRX) issued the following statement on Monday:

"In response to media inquiries, Valeant confirmed that it has several ongoing investigations, including investigations by the US Attorneys Offices for Massachusetts and the Southern District of New York, the SEC, and... More

Valeant Pharma (VRX) Says It's Under Investigation by SEC

(Updated - February 29, 2016 3:38 PM EST)

Valeant Pharma (NYSE: VRX) said it's under investigation by the SEC, according to Bloomberg, citing spokesperson Laurie Little. The probe is said to be separate from the Salix investigation.

"In response to media inquiries, Valeant confirmed that it... More